Skip to main content

Advertisement

SpringerLink
Log in

Ipilimumab

  • Fresh from the Pipeline
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

In March 2011, ipilimumab (Yervoy; Bristol-Myers Squibb), a human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA4), was approved by the US Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: T cell activation.

References

  1. Jemal, A. et al. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).

    Article  Google Scholar 

  2. Garbe, C. et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5–24 (2011).

    Article  CAS  Google Scholar 

  3. Salama, A. K. & Hodi, F. S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res. 5 Apr 2011 (doi: clincanres.2232.2011).

  4. Leach, D. R. et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).

    Article  CAS  Google Scholar 

  5. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372–8377 (2003).

    Article  CAS  Google Scholar 

  6. US FDA. FDA labeling information — Yervoy. FDA website [online], (2011).

  7. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

    Article  CAS  Google Scholar 

  9. Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).

    Article  CAS  Google Scholar 

  10. Tong, M. et al. Wells Fargo Securities, equity research. (28 March 2011).

  11. Holfrod, J. et al. Jefferies company note, Bristol-Myers Squibb. (31 March 2011).

Download references

Author information

Authors and Affiliations

  1. Vernon K. Sondak, Keiran S. M. Smalley and Ragini Kudchadkar are at the H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA. vernon.sondak@moffit.org,

    Vernon K. Sondak, Keiran S. M. Smalley & Ragini Kudchadkar

  2. Seden Grippon is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. SGrippon@uk.imshealth.com,

    Seden Grippon

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Vernon K. Sondak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keiran S. M. Smalley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ragini Kudchadkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seden Grippon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sondak, V., Smalley, K., Kudchadkar, R. et al. Ipilimumab. Nat Rev Drug Discov 10, 411–412 (2011). https://doi.org/10.1038/nrd3463

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3463

  • Springer Nature Limited

This article is cited by

Search

Navigation